Simcere Pharma kicks off $461m Hong Kong IPO

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
13 Oct 2020

Simcere Pharmaceutical Group has begun its Hong Kong listing, opening books for the up-to HK$3.57bn ($460.6m) deal.

After a week of premarketing, the issuer hit the road with sponsors CICC and Morgan Stanley on Tuesday. UBS is also working on the trade as a joint global co-ordinator, while CMB International is a bookrunner and CNCB Capital a lead manager.

Simcere is a Chinese firm ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial